GLPwatch
Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.
Med · 2024
Last updated 2026-05-28In a trial of 616 people with obesity-related heart failure and type 2 diabetes, semaglutide improved body weight, reduced inflammation, and eased heart failure symptoms. The study suggests semaglutide may offer additional benefits beyond standard treatments like SGLT2 inhibitors.
AI summary of the abstract below.
| Journal | Med, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.16 |
| NIH percentile | 11 |
| Molecules | — |
| Conditions studied | Heart Failure, Obesity, Type 2 Diabetes |
Abstract
The STEP-HFpEF DM trial showed that semaglutide improved body weight, systemic inflammation, and heart failure symptoms in people with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. By addressing both metabolic and cardiovascular risk, semaglutide is a promising therapeutic option for HFpEF in addition to SGLT2i.
Verbatim abstract via PubMed 39127032 ↗